Patient Preference and Adherence
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
(6723) Total Article Views
Authors: Haya Ascher-Svanum, Baojin Zhu, Douglas E Faries, Jonathan P Lacro, Christian R Dolder, Xiaomei Peng
Published Date March 2008
Volume 2008:2 Pages 67 - 77
Haya Ascher-Svanum1, Baojin Zhu1, Douglas E Faries1, Jonathan P Lacro2, Christian R Dolder3, Xiaomei Peng1
1Eli Lilly and Company, Outcomes Research, Indianapolis, IN, USA; 2VA San Diego Health Care System and Department of Psychiatry, University of California, San Diego, CA, USA; 3Wingate University School of Pharmacy, Wingate, NC, USA
Objective: To compare adherence and persistence to typical versus atypical antipsychotics and between specific atypical agents in the usual care of schizophrenia and to examine the association between adherence and persistence.
Method: Data were drawn from a 3-year prospective, nonrandomized, noninterventional study of schizophrenia conducted during 1997–2003. Initiators on haloperidol, risperidone, olanzapine, quetiapine, and clozapine with at least 1 year of follow-up were included (n = 878). Adherence (Medication Possession Ratio, MPR) and persistence (time to all-cause medication discontinuation) were assessed using medical record prescription information. Analyses employed multivariate statistics adjusted for group differences.
Results: Overall, 58% of the patients were deemed adherent (MPR >80%). Adherence rates were higher: for atypical (59.4%) than typical antipsychotics (34.5%, p < 0.001), for clozapine (77%) than each comparator excluding olanzapine (p < 0.01), and for olanzapine (64%) than risperidone (57%, p = 0.027) and quetiapine (52%, p = 0.019). Differences between risperidone and quetiapine were not statistically significant. Adherence and persistence were highly correlated (r = 0.957, p < 0.001).
Conclusion: In the usual care of schizophrenia, medication adherence and persistence appear to be highly correlated and to significantly differ between typical and atypical antipsychotics and among atypical agents. The choice of antipsychotic may play a meaningful role in patients’ adherence to and persistence with antipsychotic medications.
Keywords: adherence, persistence, schizophrenia, antipsychotics
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Haya Ascher-Svanum
Readers of this article also read:
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- MLA'14 -
May 16–21, 2014
- ISPOR International meeting
May 31 - June 4, 2014
- CINP World Congress
22 - 26 June, 2014
- Cancer Pharmacogenomics and Targeted Therapies
17 - 19 September, 2014
- ESMO 2014 Congress
26 - 30 September, 2014
- 27th ECNP Congress
18 - 21 October, 2014
- ISPOR 17th Annual European Congress 2014
8 - 12 November, 2014
Amsterdam, The Netherlands
- Health literacy and health seeking behavior among older men in a middle-income nation
- Prolonged rupture of membranes in term infants: should all babies be screened?
- Increasing access to quality health care for the poor: Community perceptions on quality care in Uganda
- Narcissistic rage: The Achilles’ heel of the patient with chronic physical illness